title: Lacosamide for the treatment of epilepsy.
abstract: Lacosamide is a third-generation antiepilepsy drug approved for adjunctive treatment of partial-onset seizures in adults. The pharmacology of lacosamide includes linear kinetics, complete bioavailability, and no major drug interactions. Lacosamide produces slow inactivation of neuronal sodium channels, which differentiates it from other sodium channel modulators, such as carbamazepine and phenytoin. The drug was effective with no major safety problems detected in three large placebo-controlled pivotal trials and has been released in Europe and the US at 200-400 mg/day, divided b.i.d.; an intravenous formulation is approved for temporary conversion from oral therapy. This article reviews the clinical development, pharmacology, and uses of lacosamide for treating partial-onset seizures in adults.
authors.affiliation: Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. gkrauss@jhmi.edu
authors.forename: G L
authors.initials: GL
authors.lastname: Krauss
authors.forename: H B
authors.initials: HB
authors.lastname: Edwards
authors.forename: B
authors.initials: B
authors.lastname: Lin
mesh_terms: D000081:Acetamides / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006801:Humans; D000078334:Lacosamide; D016032:Randomized Controlled Trials as Topic; D012640:Seizures / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000927:Anticonvulsants; D000078334:Lacosamide